{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:25:54Z","timestamp":1795029954917,"version":"4.10.2"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03170-y","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T02:59:47Z","timestamp":1741575587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity"],"prefix":"10.1186","volume":"23","author":[{"given":"Yanhong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingji","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"3170_CR1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119\u201332.","journal-title":"Lancet"},{"key":"3170_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"Ca-a Cancer J Clin"},{"key":"3170_CR3","doi-asserted-by":"crossref","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Reviews Disease Primers. 2017;3:17009.","DOI":"10.1038\/nrdp.2017.9"},{"key":"3170_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","volume":"70","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127\u201337.","journal-title":"Cancer Treat Rev"},{"key":"3170_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"3170_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/CCO.0000000000000621","volume":"32","author":"HV Patel","year":"2020","unstructured":"Patel HV, Shinder B, Srinivasan R, Singer EA. Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Curr Opin Oncol. 2020;32:240\u20139.","journal-title":"Curr Opin Oncol"},{"key":"3170_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Reviews Clin Oncol. 2021;18:527\u201340.","journal-title":"Nat Reviews Clin Oncol"},{"key":"3170_CR8","doi-asserted-by":"crossref","unstructured":"Li TS, Xu LJ, Wei Z, Zhang SM, Liu XY, Yang YZ, Gu Y, Zhang J. ELF5 drives angiogenesis suppression though stabilizing WDTC1 in renal cell carcinoma. Mol Cancer. 2023;22:184.","DOI":"10.1186\/s12943-023-01871-2"},{"key":"3170_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1126\/science.aaw7875","volume":"365","author":"LL Munn","year":"2019","unstructured":"Munn LL, Jain RK. Vascular regulation of antitumor immunity. Science. 2019;365:544\u20135.","journal-title":"Science"},{"key":"3170_CR10","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/0008-5472.CAN-11-4058","volume":"72","author":"Y Cao","year":"2012","unstructured":"Cao Y, E G, Wang E, Pal K, Dutta SK, Bar-Sagi D, Mukhopadhyay D. VEGF exerts an angiogenesis-independent function in Cancer cells to promote their malignant progression. Cancer Res. 2012;72:3912\u20138.","journal-title":"Cancer Res"},{"key":"3170_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune\u2013vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18:195\u2013203.","journal-title":"Nat Rev Immunol"},{"key":"3170_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457\u201374.","journal-title":"Nat Rev Cancer"},{"key":"3170_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/onc.2016.225","volume":"36","author":"S Chouaib","year":"2016","unstructured":"Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2016;36:439\u201345.","journal-title":"Oncogene"},{"key":"3170_CR14","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139\u201345.","journal-title":"Cancer Res"},{"key":"3170_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/med.21452","volume":"37","author":"R Ronca","year":"2017","unstructured":"Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S. Tumor angiogenesis revisited: regulators and clinical implications. Med Res Rev. 2017;37:1231\u201374.","journal-title":"Med Res Rev"},{"key":"3170_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in Tumor Growth and Angiogenesis. J Clin Oncol. 2005;23:1011\u201327.","journal-title":"J Clin Oncol"},{"key":"3170_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096\u2013103.","journal-title":"Nat Med"},{"key":"3170_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J. VEGFA-VEGFR pathway blockade inhibits Tumor-Induced Regulatory T-cell proliferation in Colorectal Cancer. Cancer Res. 2013;73:539\u201349.","journal-title":"Cancer Res"},{"key":"3170_CR19","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/bjc.2012.468","volume":"107","author":"NG Gavalas","year":"2012","unstructured":"Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer. 2012;107:1869\u201375.","journal-title":"Br J Cancer"},{"key":"3170_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8\u2009+\u2009T cells in tumors. J Exp Med. 2015;212:139\u201348.","journal-title":"J Exp Med"},{"key":"3170_CR21","doi-asserted-by":"crossref","unstructured":"Tang H, Wang Y, Chlewicki Lukasz K, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu Y-X. Facilitating T cell infiltration in Tumor Microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;30:500.","DOI":"10.1016\/j.ccell.2016.08.011"},{"key":"3170_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967\u201374.","journal-title":"Nature"},{"key":"3170_CR23","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.ijrobp.2004.08.002","volume":"60","author":"DW Siemann","year":"2004","unstructured":"Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiation Oncology*Biology*Physics. 2004;60:1233\u201340.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"3170_CR24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592\u2013603.","journal-title":"Nat Rev Cancer"},{"key":"3170_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","volume":"8","author":"JML Ebos","year":"2011","unstructured":"Ebos JML, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Reviews Clin Oncol. 2011;8:210\u201321.","journal-title":"Nat Reviews Clin Oncol"},{"key":"3170_CR26","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377:1345\u201356.","journal-title":"N Engl J Med"},{"key":"3170_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"3170_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"3170_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"3170_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275\u201387.","journal-title":"Nat Rev Cancer"},{"key":"3170_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250\u20134.","journal-title":"Nature"},{"key":"3170_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352.","journal-title":"Immunity"},{"key":"3170_CR33","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1172\/JCI62860","volume":"122","author":"JJ Erickson","year":"2012","unstructured":"Erickson JJ, Gilchuk P, Hastings AK, Tollefson SJ, Johnson M, Downing MB, Boyd KL, Johnson JE, Kim AS, Joyce S, Williams JV. Viral acute lower respiratory infections impair CD8\u2009+\u2009T cells through PD-1. J Clin Invest. 2012;122:2967\u201382.","journal-title":"J Clin Invest"},{"key":"3170_CR34","doi-asserted-by":"crossref","unstructured":"Watanabe H, Matsushita Y, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Miyake H. Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model. Sci Rep. 2023;13:11361.","DOI":"10.1038\/s41598-023-37857-9"},{"key":"3170_CR35","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1016\/j.biomaterials.2012.03.058","volume":"33","author":"H Gao","year":"2012","unstructured":"Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, Fan L, Xi Z, Jiang X, Zhang Q. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33:5115\u201323.","journal-title":"Biomaterials"},{"key":"3170_CR36","unstructured":"Liu Z-J, Boulina M, Ting A, Wang D, Moller M, Shao H. A novel stromal fibroblast-modulated 3D Tumor Spheroid Model for studying Tumor-Stroma Interaction and Drug Discovery. J Vis Exp. 2020;156:e60660."},{"key":"3170_CR37","doi-asserted-by":"crossref","unstructured":"Wang S, Raybuck A, Shiuan E, Cho SH, Wang Q, Brantley-Sieders DM, Edwards D, Allaman MM, Nathan J, Wilson KT et al. Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity. JCI Insight. 2020;5:e139237.","DOI":"10.1172\/jci.insight.139237"},{"key":"3170_CR38","doi-asserted-by":"crossref","unstructured":"Hong S, Zheng D-W, Zhang C, Huang Q-X, Cheng S-X, Zhang X-Z. Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vascular disruption. Sci Adv. 2020;6: eabb0020.","DOI":"10.1126\/sciadv.abb0020"},{"key":"3170_CR39","doi-asserted-by":"crossref","unstructured":"Rinchai D, Verzoni E, Huber V, Cova A, Squarcina P, De Cecco L, de Braud F, Ratta R, Dugo M, Lalli L et al. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clin Translational Med. 2021;11:e434.","DOI":"10.1002\/ctm2.434"},{"key":"3170_CR40","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1111\/cas.15081","volume":"112","author":"Y Kondo","year":"2021","unstructured":"Kondo Y, Suzuki S, Takahara T, Ono S, Goto M, Miyabe S, Sugita Y, Ogawa T, Ito H, Satou A, et al. Improving function of cytotoxic T-lymphocytes by transforming growth factor\u2010\u03b2 inhibitor in oral squamous cell carcinoma. Cancer Sci. 2021;112:4037\u201349.","journal-title":"Cancer Sci"},{"key":"3170_CR41","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1016\/j.biomaterials.2014.01.076","volume":"35","author":"Y Yang","year":"2014","unstructured":"Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide\u2013doxorubicin conjugate for tumor-specific therapy. Biomaterials. 2014;35:4368\u201381.","journal-title":"Biomaterials"},{"key":"3170_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.actbio.2016.08.029","volume":"44","author":"L Kang","year":"2016","unstructured":"Kang L, Fan B, Sun P, Huang W, Jin M, Wang Q, Gao Z. An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome. Acta Biomater. 2016;44:341\u201354.","journal-title":"Acta Biomater"}],"updated-by":[{"DOI":"10.1186\/s12951-025-03532-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000}}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03170-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:02:26Z","timestamp":1750777346000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03170-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3170"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03170-y","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u201cThe original online version of this article was revised\u201c: Fig. 5 has been updated","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12951-025-03532-6","URL":"https:\/\/doi.org\/10.1186\/s12951-025-03532-6","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted with the approval of the Laboratory Animal Ethics Committee of the Institute of Materia Medica in CAMS and PUMC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}